ReviewCurrent opinion in cell biology2014
Integrated approaches to understanding antipsychotic drug action at GPCRs.
Review in Current opinion in cell biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Do GPCRs constitute the target of 30% of newly approved drugs in Germany?Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Biased signalingActa pharmaceutica Sinica. B · 2025Review
- Activity of Protein Kinase A in the Frontal Cortex in Schizophrenia.Brain sciences · 2023Article
- The organic cation transporter 2 regulates dopamine D1 receptor signaling at the Golgi apparatus.eLife · 2022Article
- Role of Receptors in Relation to Plaques and Tangles in Alzheimer's Disease Pathology.International journal of molecular sciences · 2021Review
- Clozapine-induced transcriptional changes in the zebrafish brain.NPJ schizophrenia · 2020Article
- Purkinje Cell-Specific Knockout of Tyrosine Hydroxylase Impairs Cognitive Behaviors.Frontiers in cellular neuroscience · 2020Article
- Article
- Evaluation of SYA16263 as a new potential antipsychotic agent without catalepsy.Pharmacology, biochemistry, and behavior · 2019Article
- G Protein-Coupled Receptor Endocytosis Confers Uniformity in Responses to Chemically Distinct Ligands.Molecular pharmacology · 2017Article
- The Multiple Waves of Cannabinoid 1 Receptor Signaling.Molecular pharmacology · 2016Review
- GNB5 mutation causes a novel neuropsychiatric disorder featuring attention deficit hyperactivity disorder, severely impaired language development and normal cognition.Genome biology · 2016Article
- New paradigms in GPCR drug discovery.Biochemical pharmacology · 2015Review
- Molecular recognition of ketamine by a subset of olfactory G protein-coupled receptors.Science signaling · 2015Article
- Drug elucidation: invertebrate genetics sheds new light on the molecular targets of CNS drugs.Frontiers in pharmacology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The G-protein coupled receptor (GPCR) family of genes represents one of the largest druggable families of genes in the human genome. This is evident by the fact that approximately 30% of currently marketed drugs target GPCRs. However, many of these drugs are limited in their clinical potential as they are associated with debilitating side effects-a consequence of our incomplete understanding of their pharmacology and the signaling pathways regulated by GPCRs. Because of the limited range of tools available to resolve these issues, integrated approaches are required to fully understand the pharmacological action of drugs and the biochemical repertoire regulated by GPCRs. In this review we will focus on the action of antipsychotic drugs on certain monoamine GPCRs in the central nervous system (CNS) and the approaches being developed to elucidate their distinct pharmacology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.